Molecular Formula | C8H16N2O4 |
Molar Mass | 204.22 |
Melting Point | 153-155°C(lit.) |
Solubility | H2O: soluble |
Appearance | lyophilized powder |
Color | White to Light Beige |
Storage Condition | −20°C |
Stability | Hygroscopic |
MDL | MFCD00192455 |
In vitro study | Suberoyl bis-hydroxamic acid (10, 20 or 50 μM; 24 hours) combination with TRAIL improves apoptosis extent, and when TRAIL is combined with 20 μM SBHA (itself causing only 10–15% apoptosis), resulting in 45–50% cell death.Suberoyl bis-hydroxamic acid (20-50 μM; 10-20 hours) alone has little effect on the expression of the proteins Bcl-xL, Mcl-1, and has albeit mildeffect on Bax. When it combines with TRAIL,which increases the ratio of relative protein expression of Bcl-xL and Bax in early periods, while the change in the ratio of Mcl-1 and Bax increases later in MM-BI and Ist-Mes2 cells.Suberoyl bis-hydroxamic acid (30 μM; 6 hours) causes accumulation of acetylated histone H4 in MEL cells. Apoptosis Analysis Cell Line: MM-BI and Ist-Mes2 cells Concentration: 10 μM, 20 μM or 50 μM Incubation Time: 24 hours Result: Showed a cooperative effect in cell apoptosis. |
In vivo study | Suberoyl bis-hydroxamic acid (intraperitoneal injection; 200 mg/kg; every 2 days; 12 days) reveals a marked increase in the active form of Notch1 (NICD) with a concomitant decrease in ASCL1. It reduces the MTC tumor growth. Animal Model: Nude mice injected with human MTC cells Dosage: 200 mg/kg Administration: Intraperitoneal injection; every 2 days; 12 days Result: Resulted in an average 55% inhibition of tumor growth in SBHA treatment group. |
Safety Description | S22 - Do not breathe dust. S24/25 - Avoid contact with skin and eyes. |
WGK Germany | 3 |